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Abstract
Background: Enterovirus 71 (EV71) has caused recurrent epidemics of hand, foot and mouth disease among
children in Singapore. Between August 2008 and July 2010, we conducted a survey to estimate the seroprevalence
of EV71 infection among children and adolescents aged 1-17 years. We compared our EV71 seroepidemiologic
findings with a previous study conducted in 1996-1997.
Methods: The survey involved the prospective collection of 1,200 residual sera from Singapore residents aged 1-17
years in two hospitals. Neutralizing antibodies to EV71 were detected by the microneutralization test. The
geometric mean titer (GMT) of EV71 antibodies and 95% confidence intervals (CI) were calculated and compared
by age groups. Statistical significance was taken as P < 0.05.
Results: The overall EV71 antibody prevalence was 26.9% (95% CI: 24.5-29.5%). It increased significantly from 14.3%
in children aged 1-6 years to 27.8% in those aged 7-12 years, and reached 38.8% in adolescents aged 13-17 years.
The seroconversion rate differed by about 12% between the consecutive age groups. The GMT of EV71 antibodies
was higher among primary school children aged 7-12 years in our study than that among the 6-12 year age group
in the 1996-1997 study.
Conclusions: Higher antibody titers were observed in children aged 1-6 years than those in the other two age
groups, indicating that most of the infections had been acquired during early childhood. EV71 infection is
common among children and adolescents in Singapore, with 39% infected by the time they are in secondary
school (13-17 years of age).
Background
Enterovirus 71 (EV71) and coxsackievirus A16 (CA16)
have caused large epidemics of hand, foot and mouth dis-
ease (HFMD) worldwide. Since EV71 was first identified
in 1969 from an infant suffering from encephalitis in
California [1], outbreaks associated with this virus have
been documented, including in Australia in 1972, Japan
in 1973 and 1978 [2,3], Bulgaria in 1975 [4], and Hungary
in 1978 [5]. EV71 infection is occasionally associated with
severe complications (such as encephalitis) and deaths in
children. Since 1997, EV71-related HFMD epidemics in
the Asia-Pacific region have been increasingly reported,
including in Sarawak, Malaysia in 1997 [6], 2000 [7,8],
2003 and 2006 [9]; Brunei in 2006 [10]; Perth, Australia
in 1999 [11]; Taiwan in 1998 [12] and 2000 [13]; Japan in
2000 and 2003 [14]; and China in 2008 [15].
In Singapore, HFMD was first recognized in an out-
break in June-July 1970, but the etiologic agent was
hitherto unknown. CA16 was associated with two other
outbreaks without serious complications or fatalities,
involving 104 individuals between September 1972 and
January 1973, and 742 individuals between September
and December 1981 [16,17]. EV71 was first isolated from
an infant with symptoms of HFMD in Singapore in 1984.
Between September and October 2000, a large EV71-
associated HFMD outbreak occurred in Singapore,
resulting in 4 deaths [18,19]. HFMD became notifiable
under the Infectious Diseases Act from 1 October 2000.
All preschool centers were closed from 1 October to 15
October 2000. By 28 October 2000, a total of 2,827 cases
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any medium, provided the original work is properly cited.were notified. The main pathologic findings in the fatal
cases were encephalitis, interstitial pneumonitis, and
myocarditis. Thereafter, EV71-associated HFMD epi-
demics occurred in 2006 and 2008, with the latter being
the largest known HFMD outbreak in Singapore [20].
HFMD is endemic in Singapore, and more than 50% of
cases occur in children below 5 years of age. Although the
predominant circulating enteroviruses change periodically,
the two major enteroviruses causing nationwide HFMD
epidemics in Singapore have been CA16 and EV71 [21].
An EV71 serologic survey in Singapore had been con-
ducted on serum samples collected from 856 children
aged 12 years or younger at a pediatric clinic at the
National University Hospital (NUH) between July 1996
and December 1997 [22]. All children who were born at
the hospital or brought for routine visits and vaccinations
during this 18-month period were included, and they did
not exhibit HFMD-related symptoms at the time of sam-
ple collection. Since then, there had not been any compre-
hensive survey to measure the EV71 seroprevalence
between or after EV71-associated HFMD epidemics in
Singapore.
Between August 2008 and July 2010, we conducted a
seroprevalence survey to estimate the levels of EV71-speci-
fic neutralizing antibodies among children and adolescents
aged between 1 and 17 years. This was the largest and
second nationally representative survey conducted to
ascertain the latest age-specific seroprevalence of EV71
infection in Singapore. We compared our findings with
the results of the 1996-1997 study to discern any signifi-
cant changes over the past decade.
Methods
EV71 seroprevalence study design
The Ministry of Health (MOH) conducted a national
pediatric seroprevalence survey between August 2008 and
July 2010 involving the prospective collection of residual
sera following the completion of routine biochemical
investigations by diagnostic laboratories in KK Women’s
and Children’s Hospital and NUH. This survey was carried
out in accordance with Section 7 of the Infectious Diseases
Act which provides for the use of residual samples for the
purpose of public health surveillance.
Sera of Singapore citizens and permanent residents who
were ethnic Chinese, Malay and Indian aged between 1-17
years attending inpatient services or day surgery were col-
lected. Patients were excluded if they were known to be
immunocompromised, on immunosupressive therapy, or
had been diagnosed with measles, mumps, rubella, chick-
enpox, diphtheria, pertussis, poliomyelitis, hepatitis B,
dengue or HFMD.
On the premise of an anticipated EV71 seroprevalence
of 33% in each of the age groups of 1-6 years, 7-12 years
and 13-17 years, the minimum sample size required for
each age group was 340, with a precision of ± 5% at 95%
confidence level. A total of 1,200 serum samples were
collected, comprising 400 in each of the three age groups.
The study protocol was approved by the Institutional
Review Board of the National University of Singapore.
EV71-specific neutralizing antibody assay
The serum samples were stored at -20°C, membrane-
filtered, and inactivated at 56°C for 30 minutes before use.
A modified microneutralization test [23] was used for
detecting neutralizing antibody against 5865/Sin/000009, a
previously characterized EV71 subgenogroup B4 strain iso-
lated from a fatal case of encephalitis during the local
HFMD epidemic in 2000 [24]. Serum sample dilutions of
1:8 to 1:1,024 were assayed, and each dilution was tested in
duplicate. Twenty-five microliters of 100 tissue culture
infective dose (TCID50) of virus was mixed with 25 μlo f
the appropriate serum dilution, and incubated at 37°C for
2 hours in the presence of CO2, followed by the addition of
100 μl of RD rhabdomyosarcoma cell suspension (at 2 ×
10
4 cells per 0.1 ml). Infected cells and controls were
observed with an inverted microscope after 3 days of incu-
bation at 37°C in 5% CO2. The highest dilution that pre-
vents the development of cytopathic effect in 50% of the
wells was considered as the antibody titer of the sample,
and a titer of ≥ 8 was considered positive. Each batch of
tests included a positive serum sample of known antibody
titer that was relatively reproducible (based on the accep-
tance criteria of a difference of less than one titer level,
with the same titer obtained on most occasions). An anti-
body-negative serum sample, and uninfected cells also
served as controls. The virus titer was determined by virus
back-titration.
Statistical analyses
For EV71 seroprevalence, we calculated the 95% confi-
dence intervals (CI) for binomial proportions using the
method of Wilson [25], and their unpaired difference using
method 10 described by Newcombe [26]. The geometric
mean titer (GMT) of positive sera and corresponding 95%
CI were computed by first taking the logarithmic transfor-
mation of the titer readings, followed by antilog transfor-
mation of the mean and its 95% CI. Comparison of the
GMT by age group was performed by first computing the
mean and 95% CI of the difference in logarithm-trans-
formed antibody titer, followed by checking if the ratio of 1
was within the confidence limits which had been antilog-
transformed [27]. Statistical analyses were carried out using
SPSS version 17.0 software (SPSS Inc, Chicago, IL).
P values of < 0.05 were considered statistically significant.
Results
T h eE V 7 1s e r o p r e v a l e n c ew a s2 6 . 9 %( 9 5 %C I :2 4 . 5 –
29.5%) among children and adolescents aged 1-17 years
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CI: 11.2–18.0%) in children aged 1-6 years to 27.8%
(23.6–32.3%) in 7-12 year olds, and reached 38.8%
(34.1–43.6%) in 13-17 year olds (Table 1). This indicated
that the seroconversion rate differed by about 12%
between consecutive age groups. The 1996-1997 study
revealed that EV71 infection was largely acquired at 2-5
years of age with the seropositive rate increasing at an
average of 12% per year in this age range.
No significant gender-specific difference in seropreva-
lence was observed; 24.4% (95% CI: 21.0–28.2%) of males
aged 1-17 years tested EV71-seropositive, compared to
29.1% (95% CI: 25.7–32.7%) among females. The EV71
seroprevalence of Malays at 34.9% (95% CI: 29.7–40.6%)
was significantly higher than that of Indians at 24.6% (95%
CI: 17.8–32.9%) and Chinese at 24.3% (95% CI: 21.5–
27.5%). There was no statistical difference in the seropre-
valence between the latter two ethnic groups.
The EV71 antibody prevalence by age showed a general
increasing trend except for a dip at the age of 8 years
(Figure 1). Children aged 9 years or older had a seropreva-
lence of at least 25%, and those aged 12 years or older
reached a steady state at approximately 40%. In the 1996-
1997 study, the EV71 seroprevalence attained a steady
state at approximately 50% in the 6-12 year age group [22].
Three EV71 antibody titer ranges were defined, i.e. low
titer (8-16), moderate titer (32-64) and high titer (128-
512). Moderate EV71 antibody levels dominated in all
three age groups (Figure 2). About half (49.8%, 95% CI:
44.4–55.3%) of all seropositive subjects displayed moderate
levels of EV71 antibody. The proportion of subjects with
moderate EV71 antibody levels increased with age, and
the difference in proportions (16.1%, 95% CI: 0.9–29.8%)
between the age groups of 1-6 years and 13-17 years was
significant. On the other hand, the proportion of subjects
with high EV71 antibody levels decreased with age, and
the differences in proportions between the age group of
1-6 years and the other two older age groups were signifi-
cant. About one-third (33.3%) of those seropositive in the
age group of 1-6 years possessed high EV71 antibody
levels, compared to 18.9% in the age group of 7-12 years,
and 16.8% in the adolescent group of 13-17 years.
A declining trend in the GMT of seropositive samples
was observed across the three age groups (Figure 3). The
GMT of EV71 antibody was higher among pre-school
children aged 1-6 years (GMT 45.0; 95% CI: 33.2–61.0)
than that in those of primary school age (7-12 years old)
(GMT 37.7; 95% CI: 31.5–45.0). However, the difference
in GMT between these two age groups was not statistically
significant (ratio of their GMT was 1.19; 95% CI: 0.84–
1.70). The GMT of EV71 antibody among pre-school chil-
dren aged 1-6 years was also not statistically significantly
higher than that among adolescents aged 13-17 years
(GMT 35.6; 95% CI: 30.7–41.1), since the ratio of their
GMT was 1.26 (95% CI: 0.90–1.77).
In comparison, the 1996-1997 study revealed that the
GMT of EV71 antibody was higher among pre-school
children aged 2-5 years (GMT 46.8; 95% CI: 34.7–63.1)
than those of formal school age (6-12 years) (GMT 28.8;
95% CI: 25.7–32.4) (P = 0.002) [22]. The GMT of EV71
antibody appeared to be higher among primary school
children aged 7-12 years in our study than those aged 6-12
years in the 1996-1997 study.
Discussion
Our study revealed that EV71 infection is very common
among Singapore children and adolescents, with 39%
infected by the time they are in secondary school (i.e.
Table 1 Age-specific prevalence (%) of EV71-specific neutralizing antibody (with 95% confidence intervals) by gender
and ethnic group
Demographics Age group (years)
1 - 6 7 - 12 13 - 17 1 - 17
All 14.3
(11.2–18.0)
27.8
(23.6–32.3)
38.8
(34.1–43.6)
26.9
(24.5–29.5)
Gender
Male 13.8
(9.8–19.1)
27.0
(21.6–33.1)
38.0
(29.9–46.9)
24.4
(21.0–28.2)
Female 14.7
(10.4–20.5)
28.7
(22.5–35.9)
39.1
(33.5–44.9)
29.1
(25.7–32.7)
Ethnic group
Chinese 14.7
(11.0–19.3)
22.6
(17.9–28.1)
36.3
(30.7–42.3)
24.3
(21.5–27.5)
Malay 16.1
(9.8–25.2)
40.6
(31.7–50.1)
45.8
(36.2–55.8)
34.9
(29.7–40.6)
Indian 7.5
(2.6–19.9)
27.0
(15.4–43.0)
37.8
(25.1–52.4)
24.6
(17.8–32.9)
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Figure 1 Prevalence (%) of EV71-specific neutralizing antibody by age. The bars indicate 95% confidence intervals.
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Page 4 of 713-17 years of age). The previous 1996-1997 study was
conducted before the first EV71-associated HFMD epi-
demic occurred in 2000. Our survey commenced in
August 2008, several months after an HFMD epidemic
started in Singapore around March 2008. This may have
contributed in part to the EV71 seroprevalence found in
our survey.
Around the same period in 2008, there were heightened
levels of EV71 activity in the Asia-Pacific region, including
Malaysia, mainland China, Hong Kong, and Taiwan [28].
In China, EV71-associated epidemics were documented in
many provinces from March to August 2008, with about
490,000 HFMD cases, including 126 fatalities reported in
2008 [15].
In our study, we only focused on EV71 seroprevalence
since serious complications and fatalities in recent HFMD
epidemics in the Western Pacific region tend to be gener-
ally associated with EV71 than other enteroviruses such as
CA16 [29]. In Singapore, 1.8% and 1.6% of the HFMD
cases were hospitalized respectively during the EV71-asso-
ciated HFMD epidemics between March and April 2006,
and between April and May 2008. This was more than
double the hospitalization rates of the epidemics caused
by CA16 (i.e. 0.8% between March and April 2005, and
0.7% between April and May 2007) [21]. EV71 is also
more prevalent among severely ill and hospitalized HFMD
patients in Taiwan [30,31]. Hospitalization rates increased
i nJ a p a ni n2 0 0 0w h e nE V 7 1w a st h em a i nc i r c u l a t i n g
strain [14]. It has been suggested that the clinical out-
comes may also be influenced by changes in EV71 neuro-
virulence and host genetic susceptibility [24,32].
Between 2000 and 2008, there were eight HFMD-
related deaths among more than 140,000 HFMD cases
notified in Singapore, with a case-fatality rate of lower
than 1 per 15,000. The ratio of the number of severe
HFMD-related cases (including fatal cases) to the num-
ber of HFMD notifications was lower than 1 per 10,000.
This suggests that the vast majority of infections are mild
or asymptomatic, and complications are rare. The four
laboratory-confirmed deaths in 2000 and 2001, and
another three serious hospitalized cases including a fatal-
ity in 2008 were all associated with EV71.
In Singapore, the HFMD epidemic in 2002 was asso-
ciated with CA16. Thereafter, there were annual epidemics
alternating between CA16 and EV71 from 2005 to 2008
[21]. In Sarawak, Malaysia, a three-year cyclical pattern of
EV71-associated epidemics with co-circulation of CA16
was observed to occur in 1997, 2000, 2003, and 2006 [9].
The re-emergence of EV71 as the predominant strain on a
three-yearly pattern after 1994 was also noted in Japan
[14]. In the past decade, the highest incidence of HFMD
in Singapore was 613.4 per 100,000 population in 2008,
which was partially associated with EV71. It remains to be
seen if EV71-associated HFMD epidemics will occur at
two to three year cycles in Singapore, and regular EV71
seroprevalence surveys on children may help to shed light
on future trends.
The reasons why EV71 causes frequent and widespread
outbreaks in the Asia-Pacific region in the past decade
remain unclear [33]. Our findings provide the latest EV71
seroprevalence data in Singapore more than one decade
after the previous study in 1996-1997. EV71 seropreva-
lence among children was observed to be lower in our
study compared to that conducted more than 10 years
ago, indicating that the pediatric population remains sus-
ceptible to EV71 infection. This reduction may be partly
attributed to the consistent emphasis on personal hygiene
and cleaner environments in pre-schools and schools.
The accumulation of children susceptible to EV71 infec-
tion may have triggered the epidemics in Singapore in
2006 and 2008. In addition, the number and capacity of
childcare centers have increased rapidly in Singapore over
the past decade. The supply and enrollment of childcare
centers are expected to continue rising, in view of the
emphasis on center-based care, in the form of infant care,
childcare and student care centers as an important conti-
nuum of care and development for children. With more
children congregating in limited spaces, thus providing
readily available reservoirs for rapid circulation of the
virus, there is a higher risk of transmission to the rest of
the population and their family members.
We could make valid comparisons of the findings
between our study and the one in 1996-1997, since the
same laboratory method was used and serum samples
were taken from children attending pediatric hospitals
for both studies. Moreover, children with symptoms of
HFMD were excluded from both studies.
In our survey, seropositive children aged 12 years
(mostly in the last year of primary school education) or
older reached a steady proportion of approximately 40%.
A declining trend in the GMT of seropositive samples
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Figure 3 Geometric mean titer (GMT) of EV71-specific
neutralizing antibody by age group. The bars indicate 95%
confidence intervals.
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Page 5 of 7was observed across the three age groups. These obser-
vations indicated that transmission was common in
pre-schools and primary schools. The GMT of EV71
antibody appeared higher among primary school children
aged 7-12 years in our study than that of the 6-12 year
age group in the 1996-1997 study. This further suggested
that in addition to pre-schools, EV71 transmission has
become more frequent in primary schools compared to
the past decade. There had also been a corresponding
shift in the age distribution of HFMD cases to older chil-
dren aged 7-12 years old, and the proportion of cases in
this age group increased significantly from 7.8% in 2001
to 17.2% in 2008 (P < 0.01, c
2 test for trend). On the
other hand, while the notifications per 100,000 popula-
tion remained highest in the pre-school population, the
proportion of cases in the age group of 1-6 years
decreased significantly from 78.7% in 2001 to 67.6% in
2008 (P < 0.01, c
2 test for trend).
The advantages and disadvantages of population-based
sampling versus laboratory-based sampling were carefully
considered before the commencement of our survey.
Laboratory-based sampling was selected as population-
based sampling may suffer from unacceptably low
response rates due to parental concerns about taking
blood samples from their children. The main source of
bias in laboratory-based sampling arises when the prob-
ability of hospital admission is dependent on the patient’s
immunity to the disease being studied. To minimize this
potential selection bias in our survey, sera of patients who
had been diagnosed with HFMD were excluded from the
survey.
Singapore has a well-developed healthcare system, and
the residual sera were collected from the two main pedia-
tric hospitals in the public sector. Of the hospital dis-
charges among children aged 1-17 years in 2009, 87%
were in the public sector. Hence, the selection bias in our
study was minimized. Laboratory-based sampling also has
an important advantage of avoiding additional discomfort
in obtaining blood samples from subjects, particularly
from young children [34]. National serosurveys using resi-
dual sera from diagnostic laboratories have been carried
out to provide seroprevalence estimates of EV71 infection
in other countries such as Germany and Vietnam [35,36].
Nonetheless, greater efforts are needed to increase
response rates of population-based sampling, e.g. through
public education.
Conclusions
Based on our findings, higher EV71-specific neutralizing
antibody titers were observed in pre-school children aged
1-6 years than those in the other two older age groups,
indicating that most of the infections had been acquired
during early childhood. Seroprevalence surveys con-
ducted periodically to measure the prevalence of EV71-
neutralizing antibody in the pediatric population in Sin-
gapore will facilitate a more in-depth understanding of
the epidemiologic trends and HFMD epidemics asso-
ciated with EV71 infections.
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